Mumbai: Radiation therapy after surgery safely reduces the risk of `pelvic relapse’ in patients with locally advanced, muscle-invasive bladder cancer, Tata Memorial Centre (TMC) Mumbai said on Tuesday.
Pelvic relapse refers to the return or progression of cancer within the pelvic area after a patient has initially responded to treatment or achieved remission.
A research study led from India, the `Bladder Adjuvant Radiotherapy (BART) trial’, is the largest randomized trial in the world to evaluate the role of radiation therapy after bladder cancer surgery, the TMC said.
Dr. Sudeep Gupta, Director of TMC, celebrated the study’s international recognition, emphasizing its potential to benefit patients globally. Dr. Vedang Murthy, leading the research, noted that modern radiation techniques significantly improve outcomes and quality of life for sufferers. The study’s success underscores India’s growing role in leading impactful health innovations.
